Note: Descriptions are shown in the official language in which they were submitted.
CA 02324381 2000-09-29
WO 99/51639 PCT/SE99/00544
AN INTEGRIN HETERODIMER AND A SUBUNIT THEREOF
FIELD OF THE INVENTION
The present invention relates to a recombinant or
isolated integrin heterodimer comprising a subunit al0
and a subunit (3, the subunit a10 thereof, homologues and
fragments of said integrin and of said subunit alO having
similar biological activity, processes of producing the
same, polynucleotides and oligonucleotides encoding the
same, vectors and cells comprising the same, binding
entities binding specifically to the same, and the use
of the same.
BACKGROUND OF THE INVENTION
The integrins are a large family of transmembrane
glycoproteins that mediate cell-cell and cell-matrix
interactions (1-5). All known members of this superfamily
are non-covalently associated heterodimers composed of an
a- and a 13-subunit. At present, 8 (3-subunits (131-(38) (6)
and 16 a-subunits (al-a9, av, aM, aL, aX, allb, aE and
aD) have been characterized (6-21), and these subunits
associate to generate more than 20 different integrins.
The 131-subunit has been shown to associate with ten dif-
ferent a-subunits, al-a9 and av, and to mediate inter-
actions with extracellular matrix proteins such as colla-
gens, laminins and fibronectin. The major collagen bind-
ing integrins are al1l and a2131 (22-25). The integrins
a3f31 and a9131 have also been reported to interact with
collagen (26,27) although this interaction is not well
understood (28). The extracellular N-terminal regions of
the a and R integrin subunits are important in the bind-
ing of ligands (29,30). The N-terminal region of the
a-subunits is composed of a seven-fold repeated sequence
(12,31) containing FG and GAP consensus sequences. The
repeats are predicted to fold into a (3-propeller domain
CA 02324381 2012-04-24
WO 99/51639 PCT/SE99/00544
2
(32) with the last three or four repeats containing puta-
tive divalent cation binding sites. The a-integrin sub-
units al, a2, aD, aE, aL, aM and aX contain a -200 amino-
acid inserted domain, the I-domain (A-domain), which
shows similarity to sequences in von Willebrand factor,
cartilage matrix protein and- complement factors C2 and B
(33,34). The I-domain is localized between the second and
third FG-GAP repeats, it contains a metal ion-dependent
adhesion site (MIDAS) and it is involved in binding of
ligands (35-38).
Chondrocytes,=the only type of cells in cartilage,
express a number of different integrins including al(3l,
a2p1, a3p1, a5pl, a6p1; avf33, and avP5 (39-41). It has
been shown that alol and a2Al mediate chondrocyte inter-
actions with collagen type II (25) which is one of the
major components in cartilage. It has alsb been shown
that a2p1 is a receptor for the cartilage matrix protein
chondroadherin (42).
SUMMARY OF THE INVENTION
The present invention relates to a novel collagen
type II binding integrin, comprising a subunit a10 in
association with a subunit P, especially subunit Pl, but
also other n-subunits may be contemplated. In preferred
embodiments, this integrin has been isolated from human
or bovine articular chondrocytes, and human chondrosar-
coma cells.
The invention also encompasses integrin homologues
of said integrin, isolated from other species, such as
bovine integrin heterodimer comprising a subunit a10 in
association with a subunit P, preferably 01, as well as
homologues isolated from other types of human cells or
from cells originating from other species.
The present invention relates in particular to a
recombinant or isolated integrin subunit a10 comprising
the amino acid sequence shown in SEQ:.I.D No. 4 or SEQ ID
No. 5,r and homologues and or fragments thereof.
CA 02324381 2012-04-24
WO 99/51639 PCTISE99/00544
3
The invention further relates to a process of pro-
ducing a recombinant integrin subunit a10 comprising
the amino acid sequence shown in SEQ ID No.4 or SEQ ID
No. 5, or homologues or fragments thereof, which process
comprises the steps of
a) isolating a polynucleotide comprising a nucleo-
tide sequence coding for a integrin subunit a10, or homo-
logues or fragments thereof,
b) constructing an expression vector comprising the
isolated polynucleotide,
c) transforming a host cell with said expression
vector,
d) culturing said transformed host cell in a culture
medium under conditions suitable for expression of inte-
grin subunit a10, or homologues or fragments thereof,
in said transformed host cell, and, optionally
e) isolating the integrin subunit a10, or homologues
or fragments thereof, from said transformed host cell or said
culture medium.
The inte4rin subunit a10, or homologues or fragments
thereof, can also be provided by isolation from _
a cell.
The invention also relates to an isolated poly-
nucleotide comprising a.nucleotide coding for a integrin
subunit a10, or homologues or fragments thereof,
which polynucleotide comp-
prises the nucleotide sequence shown in SEQ ID No. 1 or
SEQ ID No. 2, or parts thereof.
The invention further relates to an isolated poly-
nucleotide or oligonucleotide which hybridises to a DNA
or RNA encoding an integrin subunit al0, having the amino
acid sequence shown in SEQ ID No.4 or SEQ ID No 5, or
homologues or fragments thereof, wherein said polyoligo-
CA 02324381 2012-04-24
WO 99/51639 PCT1SE99100544
4 nucleotide or oligonucleotide fails to hybridise to a DNA
or RNA encoding the integrin subunit al.
The invention relates in a further aspect to vectors
comprising the above polynucleotides, and to cells con-
taining said vectors and cells that have'polynucleotides
or oligonycleotides as shown in SEQ ID No_ 1 or 2 inte-
grated in their genome_
The invention also relates to binding entities hav-
ing the capability of binding specifically to the inte-
grin subunit alO or to'homologues or fragments thereof,
such as proteins, peptides, carbohydrates, lipids, natu-
ra], ligands, polyclonal antibodies or monoclonal anti-
bodies.
In a further aspect, the invention relates to a
recombinant or isolated integrin heterodimer comprising
a subunit alO and a subunit 3, in which the subunit a10
comprises the amino acid sequence shown in SEQ ID No. 4
or SEQ ID NO.5, or homologues or fragments thereof.
In a preferred embodiment thereof, the subunit is
Pl.
The invention also relates to a process of producing
a recombinant integrin heterodimer comprising a subunit
alO and a subunit P, in which the subunit a10 comprises
the amino acid sequence shown in SEQ ID No. 4 or SEQ ID
No. 5, which process comprises the steps of
a) isolating one polynucleotide comprising a nucleo-
tide sequence coding for a subunit a10 of an integrin
heterodimer and, optionally, another polynucleotide com-
prising a nucleotide sequence coding for a subunit P of
an integrin heterodimer, or for homologues or fragments
thereof,
b) ..constructing an expression vector comprising said
isolated polynucleotide coding for said subunit a10 in
combination with an expression vector comprising said
isolated nucleotide coding for said subunit
CA 02324381 2011-07-25
WO 99/51639 PCT/SE99/00544
c) transforming a host cell with said expression
vectors,
d) culturing said transformed host cell in a culture
medium under conditions suitable for expression of an
5 integrin heterodimer comprising a subunit a10 and a sub-
unit P, or homologues or fragments thereof, in said
transformed host cell, and, optionally,
e) isolating the integrin heterodimer comprising a
subunit a10 and a subunit P, or homologues or fragments
thereof, from said transformed host cell or said
culture medium.
The integrin heterodimer, or homologues or fragments
thereof, can also be provided by isolation from a cell.
The invention further relates to a cell containing a
first vector, said first vector comprising a polynucleo-
tide coding for a subunit a10 of an integrin heterodimer,
or for homologues or parts thereof,
which polynucleotide comprises the
nucleotide sequence shown in SEQ ID No. 1 or SEQ ID No. 2
or parts thereof, and, optionally, a second vector, said
second vector comprising a polynucleotide coding for a
subunit R of an integrin heterodimer, or for homologues
or fragments thereof.
In still another aspect, the invention relates to
binding entities having the capability of binding.speci-
fically to the integrin heterodimer comprising a subunit
a10 and a subunit i, or to homologues or fragments there-
of, preferably wherein
the subunit (3 is Al. Preferred binding entities are pro-
teins, peptides, carbohydrates, lipids, natural ligands,
polyclonal antibodies and monoclonal antibodies.
In a further aspect, the invention relates to a
fragment of the integrin subunit a10, which fragment is
a peptide chosen from the group comprising peptides of
CA 02324381 2012-04-24
WO 99/51639 PCT/SE99/00544
6
the cytoplasmic domain, the I -domain and the spliced
domain.
In one embodiment, said fragment is a peptide com-
prising the amino acid sequence KLGFFAHKKIPEEEKREEKLEQ.
In another embodiinent,*said fragment comprises the
amino acid sequence from about amino acid no. 952 to
about amino acid no. 986 of SEQ ID No.4.
In a further embodiment, said fragment comprises
the amino acid sequence from about amino acid No. 140
to about amino acid No. 337 in SEQ ID No.4.
Another embodiment of the invention relates to a
polynucleotide or oligonucleotide coding for a fragment
of the human integrin subunit alO. In one embodiment this
polynucleotide of oligonucleotide codes for a fragment
which is a peptide chosen from the group comprising pep-
tides of the cytoplasmic domain, the I-dotnain and the
spliced domain. In further embodiments the polynucleotide
or oligonucleotide codes for the fragments defined above.
The invention also relates to binding entities hav-
ing the capability of binding specifically to a fragment
of the integrin subunit alO as defined above.
The invention also relates to a process of using an
integrin subunit a10 comprising the amino acid sequence
shown in SEQ ID No. 4 or SEQ ID No: 5, or an integrin
heterodimer comprising said subunit alO and a subunit (3,
or a homologue or fragment of said integrin or subunit
having similar biological activity, as a marker or target
molecule of cells or tissues expressing said integrin
subunit alO, which cells or tissues are of animal includ-
ing human origin.
In an embodiment of this process the fragment is a
peptide chosen from the group comprising peptides of the
cytoplasmic domain, the I-domain and the spliced domain.
In further embodiments of said process the frag-
ment is a peptide comprising the amino acid sequence
KLGFFAHKKIPEEEKREEKLEQ, or a fragment comprising the
amino acid sequence from about amino acid No. 952 to
CA 02324381 2012-04-24
WO 99/51639 PCT/SE99100544
7
about amino acid No. 986 of SEQ ID No.4, or a fragment
comprising the amino acid sequence from about amino acid
no. 140 to about amino acid no. 337 of SEQ ID no. 4.
The subunit P is preferably Pl. The cells are pre-
ferably chosen from the group comprising chondrocytes,
smooth muscle cells, endothelial cells, osteoblasts and
fibroblasts.
Said process may be used during pathological condi-
tions involving said subunit a10, such as patholbgical
conditions comprising damage of cartilage, or comprising
trauma, rheumatoid arthritis and osteoarthritis.
Said process may be used for detecting the formation
of cartilage during embryonal development, or for detect-
ing physiological or therapeutic reparation of cartilage.
Said process may also be used for selection and ana-
lysis, or for sorting, isolating or purification of chon-
drocytes.
A further embodiment of said process is a process.
for detecting regeneration of cartilage or chondrocytes
during transplantation of cartilage or chondrocytes.
A still further embodiment of said process is a pro-
cess for in vitro studies of differentiation of chondro-
cytes.
The invention also comprises a process of using
binding entities having the capability of binding speci-
fically to an integrin subunit a10 comprising the amino
acid sequence shown in SEQ ID No. 4 or SEQ ID No.5, or
an integrin heterodimer comprising said subunit alO and a
subunit I, or to homologues or fragments thereof having
similar biological activity, as markers or target mole-
cules of cells or tissues expressing said integrin sub-
unit a10, which cells or tissues are of animal including
human origin.
The fragment in said process may be a peptide chosen
from the group comprising peptides of the cytoplasmic
domain, the I-domain and the spliced domain. In prefer-
red embodiments said fragment is a peptide comprising the
CA 02324381 2012-04-24
WO 99/51639 PCT/SE99100544
=
8
amino acid sequence KLGFFAHKKIPEEEKREEKLEQ, or a fragment
comprising the amino acid sequence from about amino acid
No. 952 to about amino acid No. 986 of SEQ ID No. 4, or
a fragment comprising the amino acid sequence from about
amino I~cid No. 140 to about amino acid no. 337 of SEQ ID
No. 4.
The process may also be used for detecting the pre-
sence of an integrin subunit alO comprising the amino
acid sequence shown in SEQ ID No.4 or SEQ ID No. 5, or
of an integrin heterodimer comprising said subunit al0
and a subunit P, or of homologues or fragments thereof.
In a further embodiment said process is a process
for determining the differentiation-state of cells during
embryonic development, angiogenesis, or development of
cancer.
In a still further embodiment this process is a
process for detecting the presence of an integrin sub
unit a10, or of a homologue or fragment of said integrin
subunit, on cells,
whereby a polynucleotide or oligonucleotide chosen from
the group comprising a polynucleotide or oligonucleotide
chosen from the nucelotide sequence shown in SEQ ID No. 1
is used as a marker under hybridisation conditions where-
in said polynucleotide or oligonucleotide fails to
hybridise to a DNA or RNA encoding an integrin subunit
al. Said cells may be chosen from the group comprising
chondrocytes, smooth muscle cells, endothelial cells,
osteoblasts and fibroblasts. Said integrin fragment"may
be a peptide chosen from the group comprising peptides
of the cytoplasmic, domain, the I-domain and the spliced
domain, such as a peptide comprising the amino acid
sequence KLGFFAHKKIPEEEKREEKLEQ, or a fragment comprising
the amino acid sequence from about amino acid no. 952 to
about amino acid no. 986 of SEQ ID No. 4, or a fragment
comprising the amino acid sequence from about amino acid
No. 140 to about amino acid no. 337 of SEQ ID No.4.
CA 02324381 2012-04-24
WO 99/51639 PCT/SE99/00544
9
In a still further embodiment the process is a pro-
cess for determining the differentiation-state of cells
during development, in pathological conditions, in tissue
regeneration or in therapeutic and physiological repara-
tion of cartilage. The pathological conditions may be any
pathological conditions involving the integrin subunit
alO, such as rheumatoid arthritis, osteoarthrosis or
cancer. The cells may be chosen from the group compris-
ing chondrocytes, smooth muscle cells, endothelial cells,
osteoblasts and fibroblasts.
The invention also relates to a process for deter-
mining the differentiation-state of cells during develop-
ment, in pathological conditions, in tissue regeneration
and in therapeutic and physiological reparation of car-
tilage, whereby a polynucleotide or oligonucleotide
chosen from the nucleotide sequence shown' in SEQ ID No. 1
is used as a marker under hybridisation conditions where-
in said polynucleotide or oligonucleotide fails to
hybridise to a DNA or.RNA encoding an integrin subunit
al. Embodiments of this aspect comprise a process, where-
by said polynucleotide or oligonucleotide is a poly-
nucleotide or oligonucleotide coding for a peptide
chosen from the group comprising peptides of the cyto-
plasmic domain, the I-domain and the spliced domain,
such as a polynucleotide or oligonucleotide coding
for a peptide comprising the amino acid sequence
KLGFFAHKKIPEEEKREEKLEQ, or comprising the amino acid
sequence from. about amino acid No. 952 to about amino
acid no. 986 of SEQ ID No.4, or the amino acid sequence
from about amino acid No. 140 to about amino acid No. 337
of SEQ ID No.4. Said pathological conditions may be any
pathological conditions involving the integrin subunit
alO, such as rheumatoid arthritis, osteoarthrosis or
cancer, or atherosclerosis or inflammation. Said cells
may be chosen from the group comprising chondrocytes,
smooth muscle cells, endothelial cells, osteoblasts and
fibroblasts.
CA 02324381 2012-04-24
WO 99151639 PCTISE99100544
In a further aspect the invention relates to a phar-
maceutical composition comprising as an active ingredient
a pharmaceutical agent or an antibody which is capable of
using an integrin heterodimer comprising a subunit alO
5 and a subunit 3, or the subunit a10 thereof,'or a homo-
logue or fragment of said integrin or subunit a10 having
similar biological activity, as a target molecule. An
embodiment of said pharmaceutical composition is intended
for use in stimulating, inhibiting or blocking the forma-
10 tion of cartilage, bone or blood vessels. A further embo-
diment comprises a pharmaceutical composition for use in
preventing adhesion between tendon/ligaments and the
surrounding tissue after infection, inflammation and
after surgical intervention where adhesion impairs the
function of the tissue.
The invention is also related to a vhccine compris-
ing as an active ingredient an integrin heterodimer com-
prising.a subunit a10 and a subunit 0, or the subunit a10
thereof, or a homologue or fragment of said'.integrin or
subunit a10, or DNA or RNA coding for said integrin sub-
unit a10.
A further aspect of the invention is related to the
use of the integrin subunit a10 as defined above as a
marker or target in transplantation of cartilage or chon-
drocytes.
A still further aspect of the invention is related
to a method of using binding entities having the capabi-
lity of binding specifically to an integrin subunit a10
comprising the amino acid sequence shown in SEQ ID No- 4
or SEQ ID No. 5, or an integrin heterodimer comprising
said subunit al0 and a subunit 0, or to homologues or
fragments thereof, for
promoting adhesion of chondrocytes and/or osteoblasts to
surfaces of implants to stimulate osseointegration.
The invention is also related to the use of an inte-
grin subunit alO or an integrin heterodimer comprising
said subunit a10 and a subunit i3 as a target for anti-
CA 02324381 2000-09-29
WO 99/51639 PCT/SE99/00544
11 '
adhesive drugs or molecules in tendon, ligament, skeletal
muscle or other tissues where adhesion impairs the func-
tion of the tissue.
The invention also relates to a method of stimulat-
ing, inhibiting or blocking the formation of cartilage or
bone, comprising administration to a subject a suitable
amount of a pharmaceutical agent or an antibody which is
capable of using an integrin heterodimer comprising a
subunit alO and a subunit 13, or the subunit alO thereof,
or a homologue or fragment of said integrin or subunit
alO having similar biological activity, as a target mole-
cule.
In another embodiment the invention is related to a
method of preventing adhesion between tendon/ligaments
and the surrounding tissue after infection, inflammation
and after surgical intervention where adhesion impairs
the function of the tissue, comprising administration to
a subject a suitable amount of a pharmaceutical agent or
an antibody which is capable of using a integrin hetero-
dimer comprising a subunit a10 and a subunit 1i, or the
subunit alO thereof, or a homologue or fragment of said
integrin or subunit alO having similar biological acti-
vity, as a target molecule.
The invention also relates to a method of stimulat-
ing extracellular matrix synthesis and repair by activa-
tion or blockage of an integrin heterodimer comprising
a subunit alO and a subunit 1i, or of the subunit alO
thereof, or of a homologue or fragment of said integrin
or subunit a10 having similar biological activity.
In a further aspect the invention relates to a
method of in vitro detecting the presence of integrin
binding entities, comprising interaction of an integrin
heterodimer comprising a subunit a10 and a subunit 1i, or
the subunit a10 thereof, or a homologue or fragment of
said integrin or subunit, with a sample, thereby causing
said integrin, subunit a10, or homologue. or fragment
thereof having similar biological activity, to modulate
CA 02324381 2000-09-29
WO 99/51639 PCT/SE99/00544
12
the binding to its natural ligand or other integrin bind-
ing proteins present in said sample.
The invention also relates to a method of in vitro
studying consequences of the interaction of a human
heterodimer integrin comprising a subunit a10 and a sub-
unit (3, or the subunit alO thereof, or a homologue or
fragment of said integrin or subunit, with an integrin
binding entity and thereby initiate a cellular reaction.
Said consequences may be measured as alterations in cel-
lular functions.
A still further aspect of the inventions relates to
a method of using DNA or RNA encoding an integrin subunit
a10 or homologues or fragments thereof as a molecular
target. In an embodiment of this aspect, a polynucleotide
or oligonucleotide hybridises to the DNA or RNA encoding
an integrin subunit alO or homologues or fragments there-
of, whereby said polynucleotide or oligonucleotide fails
to hybridise to a DNA or RNA encoding en integrin subunit
al.
The invention also relates to a method of using a
human heterodimer integrin comprising a subunit alO and
a subunit t, or the subunit alO thereof, or a homologue
or fragment of said integrin or subunit, or a DNA or RNA
encoding an integrin subunit a10 or homologues or frag-
ments thereof, as a marker or target molecule during
angiogenesis.
BRIEF DESCRIPTION OF THE FIGURES
Fig.1 Affinity purification of the a10 integrin sub-
unit on collagen type II-Sepharose.
Fig. 2. Amino acid sequences of peptides from the
bovine alO integrin subunit.
Fig. 3a. Affinitypurification and immunoprecipi-
tation of the integrin subunit alO from bovine chondro-
cytes.
Fig. 3b. Affinitypurification and immunoprecipita-
tion of the integrin subunit al0 from human chondrocytes.
CA 02324381 2000-09-29
WO 99/51639 PCT/SE99/00544
13
Fig. 3c. Affinitypurification and immunoprecipita-
tion of the integrin subunit alO from human chondrosar-
coma cells.
Fig. 4. A 900 bp PCR-fragment corresponding to the
bovine integrin subunit a10
Fig. 5. Schematic map of the three overlapping alO
clones.
Fig. 6. Nucleotide sequence and deduced amino acid
sequence of the human alO integrin subunit.
Fig. 7. Northern blot of integrin a10 mRNA.
Fig. 8 Immunoprecipitation of the a10 integrin sub-
unit from human chondrocytes using antibodies against the
cytoplasmic domain of alO (a). Western blot of the a10
associated P-chain (b).
Fig. 9. Immunostaining of a10 integrin in human
articular cartilage.
Fig. 10 Immunostaining of a10 integrin in 3 day
mouse limb cartilage.
Fig 11. Immunostaining of a10 integrin in 13.5 day
mouse embryo.
Fig 12. Hybridisation of alO mRNA in various human
tissues.
Fig. 13 Immunostaining of fascia around tendon (a),
skeletal muscle (b) and heart valves (c) in 3 day mouse
limb.
Fig. 14. PCR fragments corresponding to a10 integrin
subunit from human chondrocytes, human endothelial cells,
human fibroblasts and rat tendon.
Fig 15. Partial genomic nucleotide sequence of the
human integrin subunit alO.
Fig 16. Upregulation of a10 integrin subunit in
chondrocytes cultured in alginate.
Fig 17. Immunoprecipitation of the a10 integrin sub-
unit from human smooth muscle cells
DETAILED DESCRIPTION OF THE INVENTION
The present invention demonstrate that human and
CA 02324381 2000-09-29
WO 99/51639 PCT/SE99/00544
14
bovine chondrocytes express a novel, collagen type
II-binding integrin in the 01-family. An earlier study
presented some evidence for that human chondrosarcoma
cells also express this integrin (25). Immunoprecipita-
tion -experiments using antibodies against the integrin
subunit 31 revealed that this novel a-integrin subunit
had an apparent molecular weight (Mr ) of approximately
160 kDa under reducing conditions, and was slightly
larger than the a2 integrin subunit. To isolate this
a-subunit collagen type II-binding proteins were affinity
purified from bovine chondrocytes. The chondrocyte lysate
was first applied to a fibronectin-Sepharose precolumn
and the flow through was then applied to a collagen type
II-Sepharose column. A protein with Mr of approximately
160 kD was specifically eluted with EDTA from the colla-
gen column but not from the fibronectin cblumn. The Mr of
this protein corresponded with the Mr of the unidentified
p1-related integrin subunit. The 160 kD protein band was
excised from the SDS-PAGE gel, digested with trypsin and
the amino acid sequences of the isolated peptides were
analysed.
Primers corresponding to isolated peptides amplified
a 900 bp PCR-fragment from bovine cDNA which was cloned,
sequenced and used for screening of a human articular
chondrocyte J%ZapII cDNA library to obtain the human inte-
grin a-subunit homologue. Two overlapping clones, hcl and
hc2 were isolated, subcloned and sequenced. These clones
contained 2/3 of the nucleotide sequence including the 3'
end of the cDNA. A third clone which contained the 5'end
of the a10 cDNA, was obtained using the RACE technique.
Sequence analysis of the 160 kD protein sequence showed
that it was a member of the integrin a-subunit family and
the protein was named a10.
The deduced amino acid sequence of a10 was found to
share the general structure of the integrin a-subunits
described in previously published reports (6-21). The
large extracellular N-terminal part of a10 contains a
CA 02324381 2000-09-29
WO 99/51639 PCT/SE99/00544
seven-fold repeated sequence which was recently predicted
to fold into a n-propeller domain (32). The integrin sub-
unit a10 contains three putative divalent cation-binding
sites (DxD/NxD/NxxxD) (53), a single spanning transmem-
.5 brane domain and a short cytoplasmic domain. In contrast
to most a-integrin subunits the cytoplasmic domain of a10
does not contain the conserved sequence KxGFF (R/K) R.
The predicted amino acid sequence in alO is KLGFFAH.
Several reports indicate that the integrin cytoplasmic
10 domains are crucial in signal transduction (54) and that
membrane-proximal regions of both a- and (3-integrin cyto-
plasmic domains are involved in modulating conformation
and affinity state of integrins (55-57). It is suggested
that the GFFKR motif in a-chains are important for asso-
15 ciation of integrin subunits and for transport of the
integrin to the plasma membrane (58). The'KxGFFKR domain
has been shown to interact with the intracellular protein
calreticulin (59) and interestingly, calreticulin-null
embryonic stem cells are deficient in integrin-mediated
cell adhesion (60). It is therefor possible that the
sequence KLGFFAH in a10 have a key function in regulating
the affinity between a10P1 and matrix proteins.
Integrin a subunits are known to share an overall
identity of 20-40% (61). Sequence analysis showed that
the a10 subunit is most closely related to the I-domain
containing a-subunits with the highest identity to al
(37%) and a2 (35%). The integrins alpl and a2f31 are known
receptors for both collagens and laminins (24;62;63) and
we have also recently demonstrated that a2pl interacts
with the cartilage matrix protein chondroadherin (42).
Since a10131 was isolated on a collagen type II-Sepharose,
we know that collagen type II is a ligand for a10P1. We
have also shown by affinity purification experiments that
a10f31 interacts with collagen type I but it remains to be
seen whether laminin or chondroadherin are also ligands
for this integrin.
CA 02324381 2000-09-29
WO 99/51639 PCT/SE99/00544
16
The a10 associated n-chain migrated as the 31 inte-
grin subunit both under reducing and non-reducing condi-
tions. To verify that the alO associated n-chain indeed
is P1, chondrocyte lysates were immunoprecipitated with
antibodies against alO or P1 followed by Western blot
using antibodies against the (3l-subunit. These results
clearly demonstrated that alO is a member of the
fit-integrin family. However, the possibility that alO
combine also with other n-chains can not be excluded..
A polyclonal peptide antibody raised against the
cytoplasmic domain of alO precipitated two protein bands
with M. of approximately 160 kD (a10) and 125 kD (p1)
under reducing conditions. Immunohistochemistry using the
alO-antibody showed staining of the chondrocytes in tis-
sue sections of human articular cartilage. The antibody
staining was clearly specific since preintubation of the
antibody with the alO-peptide completely abolished the
staining. Immunohistochemical staining of mouse limb
sections from embryonic tissue demonstrated that alO is
upregulated during condensation of the mesenchyme. This
indicate that the integrin subunit a10 is important
during the formation of cartilage. In 3 day old mice a10
was found to be the dominating collagen binding integrin
subunit which point to that alO has a key function in
maintaining normal cartilage functions.
Expression studies on the protein and mRNA level
show that the distribution of alO is rather restrictive.
Immunohistochemistry analyses have shown that a10 inte-
grin subunit is mainly expressed in cartilage but it is
also found in perichondrium, periosteum, ossification
groove of Ranvier, in fascia surrounding tendon and ske-
letal muscle and in the tendon-like structures in the
heart valves. This distribution point to that alO
integrin subunit is present also on fibroblasts and
osteoblasts. PCR amplification of cDNA from different
cell types revealed the presence of an alternatively
spliced a10 integrin subunit. This spliced a10 was domi-
CA 02324381 2009-03-06
WO 99/51639 PCT/SE99100544
17
nating in fibroblasts which suggests that a10 in fibro-
blasts may have a different function compared to alO pre-
sent on chondrocytes.
Expression of the integrin subunit alO was found to
decrease when chondrocytes were cultured in monolayer. In
contrast, the expression of a10 was found to increase
when the cells were cultured in alginate beads. Since the
latter culturing model is known to preserve the phenotype
of chondrocytes the results suggest that alO can function
as marker for a differentiated chondrocyte.
Adhesion between tendon/ligaments and the surround-
ing tissue is a well-known problem after infection,
injury and after surgical intervention. Adhesion between
tendon and tendon sheets impairs the gliding function and
cause considerable problems especially during healing of
tendons in e.g. the hand and fingers.leading to func-
tional incapacity. The localisation of the a10 integrin
subunit in the fascia of tendon and skeletal muscle makes
alO a possible target for drugs and molecules with anti-
adhesive properties that could prevent impairment of the
function of tendon/ligament. The integrin subunit a10 can
also be a target for drugs or molecules with anti-adhe-
sive properties in other tissues where adhesion is a
problem.
EXAMPLES
Example 1
Affinity purification of the al0integrin subunit on
collagen type II-SepharoseTM.
Materials and Methods
Bovine chondrocytes, human chondrocytes or human
chondrosarcoma cells were isolated as described earlier
[Holmvall et al, Exp Cell Res, 221, 496-503 (1995),
Camper et al, JBC, 273, 20383-20389 (1998)]. A Triton
X-100TH lysate of bovine chondrocytes was applied to a
fibronectin-Sepharose precolumn followed by a collagen
CA 02324381 2000-09-29
WO 99/51639 PCT/SE99/00544
18
type II-Sepharose column and the integrin subunit a10 was
eluted from the collagen type II-column by EDTA (Camper
et al, JBC, 273, 20383-20389 (1998). The eluted proteins
were precipitated by methanol/chloroform, separated by
SDS-PAGE under reducing conditions and stained with
Coomassie blue. (Camper et al, JBC, 273, 20383-20389
(1998). Peptides from the alO protein band were isolated
by in-gel digestion with a trypsin and phase liquid chro-
matography and sequenced by Edman degradation (Camper et.
al, JBC, 273, 20383-20389 (1998).
Results
Fig 1 shows EDTA-eluted proteins from the fibronec-
tin-Sepharose (A), flow-through from the collagen type
II-Sepharose column (B) and EDTA-eluted proteins from the
collagen type II-Sepharose (C). The alO integrin subunit
(160 kDa) which was specifically eluted from the collagen
type II column is indicated with an arrow. Figure 2 shows
the amino acid sequences of six peptides that were iso-
lated from the bovine integrin subunit a10. Figures 3 a,
b, and c show that the a10 integrin subunit is present
on bovine chondrocytes (3a), human chondrocytes (3b) and
human chondrosarcoma cells (3c). The affinity for colla-
gen type II, the coprecipitation with ail-integrin subunit
and the molecular weight of 160 kDa under reducing condi-
tions identify the a10 integrin subunit on the different
cells. These results show that alO can be isolated from
chondrocytes and from chondrosarcoma cells.
Example 2
Amplification of:PCR fragment corresponding to
bovine alO integrin subunit.
Materials and methods
The degenerate primers GAY AAY ACI GCI CAR AC
(DNTAQT, forward) and TIA TIS WRT GRT GIG GYT (EPHHSI,
reverse) were used in PCR (Camper et al, JBC, 273, 20383-
20389 (1998) to amplify the nucleotide sequence corre-
sponding to the bovine peptide 1 (Figure 2). A 900 bp
CA 02324381 2000-09-29
WO 99/51639 PCT/SE99/00544
19
PCR-fragment was then amplified from bovine cDNA using an
internal specific primer TCA GCC TAC ATT CAG TAT (SAYIQY,
forward) corresponding to the cloned nucleotide sequence
of peptide 1 together with the degenerate primer ICK RTC
CCA RTG ICC IGG (PGHWDR, reverse) corresponding to the
bovine peptide 2 (Figure2). Mixed bases were used in
positions that were twofold degenerate and inosines were
used in positions that are three- or fourfold degenerate.
mRNA isolation and cDNA synthesis was done as earlier
described (Camper et al, JBC, 273, 20383-20389 (1998)).
The purified fragment was cloned, purified and sequenced
as earlier described (Camper et al, JBC, 273, 20383-20389
(1998)).
Results
The nucleotide sequence of peptide 1 (Figure 2)
was obtained by PCR-amplification, cloninkj and sequenc-
ing of bovine cDNA. From this nucleotide sequence an
exact primer was designed and applied in PCR-amplifica-
tion with degenerate primers corresponding to peptides
2-6 (Figure 2). Primers corresponding to peptides 1
and 2 amplified a 900;bp PCR-fragment from bovine cDNA
(Figure 4).
Example 3
Cloning and sequence analysis of the human alO inte-
grin subunit
Material and methods
The cloned 900bp PCR-fragment, corresponding to
bovine alO-integrin, was digoxigenin-labelled according
to the DIG DNA labelling kit (Boehringer Mannheim) and
used as a probe for screening of a human articular chon-
drocyte %ZapII cDNA library (provided by Michael Bayliss,
The Royal Veterinary Basic Sciences, London, UK)(52).
Positive clones containing the pBluescript SK+ plasmid
with the cDNA insert were rescued from the ZAP vector by
in vivo excision as described in the ZAP-cDNA synthesis
kit (Stratagene). Selected plasmids were purified and
CA 02324381 2000-09-29
WO 99/51639 PCT/SE99/00544
sequenced as described earlier (Camper et al, JBC, 273,
20383-20389 (1998)) using T3, T7 and internal specific
primers. To obtain cDNA that encoded the 5' end of a10 we
designed the primer AAC TCG TCT TCC AGT GCC ATT CGT GGG
5 (reverse; residue 1254-1280 in alO cDNA) and used it for
rapid amplification of the cDNA 5' end (RACE) as describ-
ed in the Marathon TM cDNA Amplification kit (Clontech
INC., Palo Alto, CA).
Results
10 Two overlapping clones, hcl and hc2 (Figure 5), were
isolated, subcloned and sequenced. These clones contained
2/3 of the nucleotide sequence including the 3' end of
the cDNA. A third clone (racel; Figure 5), which contain-
ed the 5'end of the a10 cDNA, was obtained using the
15 RACE technique. From these three overlapping clones of
a10 cDNA, 3884 nucleotides were sequenced` The nucleotide
sequence and deduced amino acid sequence is shown in
Figure 6. The sequence contains a 3504-nucleotide open.
reading frame that is predicted to encode a 1167 amino
20 acid mature protein. The signal peptide cleavage site is
marked with an arrow, human homologues to bovine peptide
sequences are underlined and the I-domain is boxed. Metal
ion binding sites are indicated with a broken underline,
potential N-glycosylation sites are indicated by an
asterisk and the putative transmembrane domain is double
underlined. The normally conserved cytoplasmic sequence
is indicated by a dot and dashed broken underline.
Sequence analysis demonstrate that a10 is a member
of the integrin a-subunit family.
Example 4
Identification of a clone containing a splice
variant of a10
One clone which was isolated from the human chon-
drocyte library (see Example 3) contained a sequence
that was identical to the sequence of al0 integrin sub-
unit except that the nucleotides between nt positions
CA 02324381 2000-09-29
WO 99/51639 PCT/SE99/00544
21
2942 and 3055 were deleted. The splice variant of a10
was verified in PCR experiment using primers flanking
the splice region (see figure 14).
Example 5
Identification of alO integrin subunit by Northern
blot
Material and methods
Bovine chondrocyte mRNA was purified using a
QuickPrep Micro mRNA Purification Kit (Pharmacia Biotech,
Uppsala, Sweden), separated on a 1% agarose-formaldehyde
gel, transferred to nylon membranes and immobilised by UV
crosslinking. cDNA-probes were 32P-labelled with Random
Primed DNA Labeling Kit (Boehringer Mannheim). Filters
were prehybridised for 2-4 hours at 42 C in 5x SSE,
5x Denharts solution, 0.1 % SDS, 50 g/mlisalmon sperm
DNA and 50% formamide and then hybridised over night
at 42 C with the same solution containing the specific
probe (0.5-1 x 106 cpm/ml). Specifically bound cDNA-
probes were analysed using the phosphoimager system
(Fuji). Filters were stripped by washing in 0.1% SDS,
forl hour at 80 C prior to re-probing. The alO-integrin
cDNA-probe was isolated from the racel-containing plasmid
using the restriction enzymes BamHI (GIBCO BRL) and NcoI
(Boehringer Mannheim). The rat 31-integrin cDNA probe was
a kind gift from Staffan Johansson, Uppsala, Sweden.
Results
Northern blot analysis of mRNA from bovine chondro-
cytes showed that a human alO cDNA-probe hybridised with
a single mRNA of approximately 5.4 kb (Figure 7). As a
comparison, a cDNA-probe corresponding to the integrin
subunit al was used. This cDNA-probe hybridised a mRNA-
band of approximately 3.5 kb on the same filter. These
results show that a cDNA-probe against alO can be used to
identify the alO integrin subunit on the mRNA level.
CA 02324381 2000-09-29
WO 99/51639 PCT/SE99/00544
22
Example 6.
Preparation of antibodies against the integrin sub-
unit a10
A peptide corresponding to part of the alO cytoplas-
mic domain, Ckkipeeekreekle (see figure 6) was synthesis-
ed and conjugated to keyhole limpet hemocyanin (KLH).
Rabbits were immunised with the peptide-KLH conjugate
to generate antiserum against the integrin subunit a10.
Antibodies recognising a10 were affinity purified on an
peptide-coupled column (Innovagen AB).
Example 7
Immunoprecipitation of the integrin subunit a10 from
chondrocytes
Material and methods
Human chondrocytes were 125I-labelled, lyzed with
Triton X-100 and immunoprecipitated as earlier described
(Holmvall et al, Exp Cell Res, 221, 496-503 (1995),
Camper et al, JBC, 273, 20383-20389 (1998)). Triton X-100
lysates of 1251-labeled human chondrocytes were immuno-
precipitated with polyclonal antibodies against the inte-
grin subunits 01, al, a2, a3 or a10. The immunoprecipi-
tated proteins were separated by SDS-PAGE (4-12%) under
non-reducing conditions and visualised using a phospho-
imager. Triton X-100 lysates of human chondrocytes immu-
noprecipitated with a10 or P1 were separated by SDS-PAGE
(8%) under non-reducing conditions and analysed by
Western blot using the polyclonal Al antibody and chemi-
luminescent detection as described in Camper et al, JBC,
273, 20383-20389 (1998).
Results
The polyclonal peptide antibody, raised against the
cytoplasmic domain of a10, precipitated two protein bands
with Mr of approximately. 160 kD (a10) and 125 kD (131)
under reducing conditions. The a10 associated 13-chain
migrated as the 01 integrin subunit (Figure 8a). To
verify that the a10 associated 13-chain in chondrocytes
CA 02324381 2000-09-29
WO 99/51639 PCT/SE99/00544
23
indeed is P1, chondrocyte lysates were immunoprecipitated
with antibodies against alO orb (3l followed by Western
blot using antibodies against the p1-subunit (Figure 8b).
These results clearly demonstrated that a10 is a member
of the fit-integrin family. However, the results do not
exclude the possibility that a10 can associate with other
n-chains in other situations.
Example 8
3mmunohistochemical'staining of the integrin subunit
alO in human and mouse cartilage
Material and methods
Frozen sections of adult cartilage (trochlear
groove) obtained during surgery (provided by Anders
Lindahl, Salgrenska Hospital, Gothenburg, Sweden and
frozen sections from of 3 day old mouse limb were fixed
and prepared for immunohistochemistry as earlier describ-
ed (Camper et al, JBC, 273, 20383-20389 (1998)). Expres-
sion of alO integrin subunit was analysed using the poly-
clonal antibody against the cytoplasmic domain as a pri-
mary antibody (see Example 6) and a secondary antibody
conjugated to peroxidase.
Results
Figures 9 show immunostaining of human adult articu-
lar cartilage.
The alO-antibody recognising the cytoplasmic domain
of a10 stained the chondrocytes in tissue sections of
human articular cartilage (A). The staining was depleted
when the antibody was-preincubated with the a10- peptide
(B). A control antibody recognising the a9 integrin sub-
unit did not bind to the chondrocyte (C).
Figures 10 showsithat the a10 antibody stain the
majority of chondrocytes in the growing bone anlage (a
and b). The a10 antibody also recognised cells in the
ossification groove of Ranvier (b), especially the
osteoblast in the bone bark which are lining the carti-
lage in the metaphys are highly positive for a10. The
CA 02324381 2000-09-29
WO 99/51639 PCT/SE99/00544
24
cells in the ossification groove of Ranvier are believed
to be important for the growth in diameter of the bone.
The integrin subunit alO is also highly expressed in
perichondrium and periosteum. Cell in these tissues are
likely important in the repair of the cartilage tissue.
The described localisation of the integrin subunit alO
suggest that this integrin is important for the function
of the cartilage tissue.
Example 9
Immunohistochemical staining of the integrin subunit
alO during mouse development
Material and methods
Frozen sections from mouse embryos (13.5 days) were
investigated for expression of alO by immunhistochemi-
stry as described in Camper et al, JBC, 2173, 20383-20389
(1998). Expression of alO integrin subunit was analysed
using the polyclonal antibody against the cytoplasmic
domain as a primary antibody (see Example 6) and a secon-
dary antibody conjugated to peroxidase. The embryo sec-
tions were also investigated for expression of integrin
subunit al (monoclonal antibody from Pharmingen) and
collagen type II (monoclonal antibody, kind, gift from
Dr John Mo, Lund University, Sweden).
Results
Figure 11 show that alO integrin subunit is unregu-
lated in the limb when the mesenchymal cells undergo con-
.densation to form cartilage (a). Especially the edge of
the newly formed cartilage has high expression of alO.
The formation of cartilage is verified by the high
expression of the cartilage specific collage type II (b).
The control antibody against al integrin subunit showed
only weak expression on the cartilage (c). In other expe-
riments expression of;alO was found in all cartilage con-
taining tissues in the 3 day old mouse including limbs,
ribs and vertebrae. The upregulation of a10 during forma-
tion of cartilage suggest that this integrin subunit is
CA 02324381 2000-09-29
WO 99/51639 PCT/SE99/00544
important both in the development of cartilage and bone
and in the repair of damaged cartilage tissue.
Example 10
5 mRNA expression of a10 in tissues other than articu-
lar cartilage
Material and methods
Expression of alO integrin subunit was examined on
the mRNA level in different human tissues. A Northern dot
10 blot with immobilised mRNA from the listed tissues in
Figure 12 was hybridised with an a10 integrin cDNA probe
isolated from the race 1-containing plasmid using the
restriction enzymes BamHl and Ncol. The degree of hybrid-
isation was analysed using a phospho imager. The follow-
15 ing symbols denote mRNA level in increasing order: -, +,
++, +++, ++++. `
Results
Analysis of the hybridised mRNA showed that a10
was expressed in aorta, trachea, spinal cord, heart,
20 lung, and kidney (Figure 12). All other tissues appear-
ed negative for alO expression. These results point to
a restricted distribution of the alO integrin subunit.
Example 11
25 Immunohistochemical staining of alO in fascia around
tendon and skeletal muscle and in tendon structures in
heart valves.
Materials and methods
Frozen sections of adult cartilage (trochlear
groove) obtained during surgery (provided by Anders
Lindahl, Salgrenska Hospital, Gothenburg, Sweden and
frozen sections from of 3 day old mouse limb were fixed
and prepared for immunohistochemistry as earlier describ-
ed (Camper et al, JBC, 273, 20383-20389 (1998)). Expres-
sion of alO integrin subunit was analysed using the poly-
clonal antibody against the cytoplasmic domain as a pri-
CA 02324381 2000-09-29
WO 99/51639 PCT/SE99/00544
26
mary antibody (see Example 6) and a secondary antibody
conjugated to peroxidase.
Results
As shown in figures 13 expression of a10 was found
in the fascia surrounding tendon (a) and skeletal muscle
(b) and in the tendon structures in the heart valves (c).
This localisation suggest that alO can bind to other
matrix molecules in addition to the cartilage specific
collagen type II. The localisation of the integrin alO on
the surface of tendons indicate that alO can be involved
in unwanted adhesion that often occurs between tendon/
ligaments and the surrounding tissue after infection,
injury or after surgery.
Example 12
mRNA expression of.alO integrin subunit in chondro-
cytes, endothelial cells and fibroblasts.
Material and methods
Isolation of mRNA, synthesis of cDNA and PCR ampli-
fication was done as earlier described (Camper et al,
JBC, 273, 20383-20389 (1998)).
Results
Figure 14-shows PCR amplification of alO cDNA from
human articular chondrocytes (lanes A6 and Bl), human
umbilical vein endothelial cells (lane A2), human fibro-
blasts (lane A4) and rat tendon (Fig 14b, lane B2). Lanes
1, 3, and 5 in figure:14 A show amplified fragments cor-
responding to the integrin subunit a2 in endothelial
cells, fibroblasts and chondrocytes, respectively. cDNA-
primers corresponding to the a10 sequence positions nt
2919-2943 (forward) and nt 3554-3578 (reverse) (see
Figure 6) were used to amplify a10 cDNA from the diffe-
rent cells. The figure shows that alO was amplified in
all three cell types. Two fragments of a10 was amplified
which represent the intact form of al0 (larger fragment)
and a splice variant (smaller fragment).. The larger frag-
CA 02324381 2000-09-29
WO 99/51639 PCTISE99/00544
27
ment was dominating in chondrocytes while the smaller
fragment was more pronounced in tendon (B2).
Example 13
Construction of alO mammalian expression vector.
The full length protein coding sequence of alO (com-
bined from 3 clones, see figure 6) was inserted into the
mammalian expression vector, pcDNA3.1/Zeo (Invitrogen).
The vector contains SV40 promoter and Zeosin selection
sequence. The alO containing expression vector was trans-
fected into cells that express the P1-integrin subunit
but lack expression of the a10 subunit. Expression of the
alO integrin subunit on the cell surface can be analysed
by immunoprecipitation and/or flow cytometry using anti-
bodies specific for alO. The ligand binding capacity and
the function of the inserted a10 integrin' subunit can be
demonstrated in cell adhesion experiment and in
signalling experiments.
Example 14
Construction of mammalian expression vector contain-
ing a splice variant of a10.
The full length protein coding sequence of the
splice variant of alO (nt,2942-nt3055 deleted) was
inserted into the mammalian expression vector pcDNA3
(see Example 13). Expression and function of the splice
variant can be analysed as described in example 13 and
compared with the intact alO integrin subunit.
Example 15
Partial isolation and characterisation of the alO
integrin genomic DNA
Material and methods
Human alO cDNA, isolated from the racel-containing
plasmid using the restriction enzymes BamHI (GIBCO BRL)
and NcoI (Boehringer Mannheim), was 32P-labelled and used
as a probe for screening of a mouse 129 cosmid library
CA 02324381 2000-09-29
WO 99/51639 PCT/SE99/00544
28
(provided by Reinhard Fassler, Lund University). Positive
clones were isolated and subcloned. Selected plasmids
were purified and sequenced as described earlier (Camper
et al, JBC, 273, 20383-20389 (1998)) using T3, T7 and
internal specific primers. Primers corresponding to mouse
genomic DNA were then constructed and used in PCR to
amplify and identify the genomic sequence of alO from the
cosmid clones.
Results
Figure 15 shows 7958 nt of the alO gene. This par-
tial genomic DNA sequence of alO integrin contains 8
exons, and a Kozak sequence. The mouse genomic alO
sequence was used to generate a targeting vector for
knockout experiments.
Example 16
Upregulation of a10 integrin subunit in chondrocytes
cultured in alginate beads
Material and methods:'
Human chondrocytes cultured in monolayer for 2 weeks
were detached with trypsin-EDTA and introduced into algi-
nate beads. Chondrocytes cultured in alginate are known
to preserve their phenotype while chondrocytes cultured
in monolayer are dedifferentiated. After 11 days chondro-
cytes cultured either in alginate or on monolayer were
isolated and surface labelled with 1251. The alO integrin
subunit was then immunoprecipitated with polyclonal
antibodies recognising the cytoplasmic domain of alO
(see Example 6 and Camper et al, JBC, 273, 20383-20389
(1998)).
Results
As shown in figure 16 chondrocytes cultured in algi-
nate beads (lanes 3 and 4) upregulated their protein
expression of alOpl. This was in contrast to chondrocytes
cultured in monolayer (lanes 1 and 2) which had a very
low expression of a10(31. Immunoprecipitation with ab con-
trol antibody is shown in lanes 1 and 3.It is known that
CA 02324381 2012-04-24
WO 99751639 FCT/SE99/00544
29
chondrocytes preserve their cartilage specific matrixpro-
duction in alginate cultures but not in monolayer culture
which point to that alginate preserve the phenotype of
chondrocytes. These results support that alO integrin
subunit can be used as a marker for differentiated chdn-
drocytes.
Example 17
Immunoprecipitation of the a10 integrin subunit from
human smooth muscle cells.
Material and methods
Human smooth muscle cells were isolated from human
aorta. After one week in culture the cells were 1251__
labelled, lysed and immunoprecipitated with antibodies
against the integrin subunit (31 (lane 1), al (lane 2), a2
(lane 3), alO (lane 4),! a3 (lane 5), control (lane 6)
(Figure 17). The experiment was done as described in
Example 7.
Results
The alO antibody precipitated two bands from the
smooth muscle cells corresponding to the a10 and the (31
integrin subunit (Fig. 17).
Example 18
Construction of bacterial expression vector contain-
ing sequence for alO splice region.
A plasmid for intracellular expression in E. coli
of the alternatively 'spliced region (amino acid pos.
952-986, SEQ. ID 4) was constructed as described. The
alternatively spliced.region were back-translated using
the E. coli high frequency codon table, creating a cDNA
sequence of 96% identity with the original sequence (SEQ.
ID 1 nucleotide pos 2940-3044). Using sequence overlap
extension (Horton et al., Biotechniques 8:528, 1990)
primer al0pfor (tab. I) and.al0prev (tab. I) was used
to generate a double stranded fragment encoding the alO
amino acid sequence. This fragment was used as a PCR
CA 02324381 2012-04-24
WO 99/51639 PCT/SE99/00544
template with primers al0pfor2 (tab. I) and al0prev2
(tab. I) in order to generate restriction enzyme site
for sub-cloning in a pET vector containing the Z-domain
of staphylococcal protein A, creating a fusion of the a10
5 spliced region with the amino.terminal of the Z-domain
with trombin cleavage site residing in-between. The frag-
ment generated in the second PCR reaction is shown (SEQ
ID No.6) also indicating the unique restriction enzymes
used for sub-cloning in the expression vector.
Table I
al0pfor 5'-
GTTCAGAACCTGGGTTGCTACGTTGTTTCCGGTCTGATCATCTCCGC
TCTGCTGCCGGCTGT-3'
alOpfor2 5'- GGGGCATATGGTTCAGAACCTGGGTTGCTACGTTG-3'
al0 rev 5' -
GATAACCTGGGACAAGCTTAGGAAGTAGTTACCACCGTGAGCAACAG
CCGGCAGCAGAGCGGA-"3'.
al0prev2 5'-
GGGGGGATCCGCGCGGCACCAGGCCGCTGATAACCTGGGACAAGCTT
AGGAAGT-3'
CA 02324381 2000-09-29
WO 99/51639 PCT/SE99/00544
31
REFERENCES
1. Springer, T.A. (1990) Nature 346, 425-434
2. Ruoslahti, E. (1991) J. Clin. Invest. 87, 1-5
3. Hynes, R.O. (1992) Cell 69, 11-25
.4. Hemler, M.E. (1988) Immunol.Today 9, 109-113
5. Yamada, K.M. (1991) J.Biol.Chem. 266, 12809-12812
6. Palmer, E.L., Ruegg, C., Ferrando, R., Pytela, R.,
and Sheppard, D. (1993) J.Cell Biol. 123, 1289-1297
7. Takada, Y., Elices, M.J., Crouse, C., and Hemler,
M.E. (1989) EMBO J. 8, 1361-1368
8. Poncz, M., Eisman, R., Heidenreich, R., Silver, S.M.,
Vilaire, G., Surrey, S., Schwartz, E., and Bennett,
J.S. (1987) J.Biol.Chem. 262, 8476-8482
9. Larson, R.S., Corbi, A.L., Berman, L., and Springer,
T. (1989) J.Cell Biol. 108, 703-712
10. Corbi, A.L., Kishimoto, T.K., Miller,` L.J., and
Springer, T.A. (1988) J.Biol.Chem. 263, 12403-12411
11. Argraves, W.S., Suzuki, S., Arai, H., Thompson, K.,
Pierschbacher, M.D.,and Ruoslahti, E. (1987) J.Cell
Biol. 105, 1183-1190-
12. Corbi, A.L., Miller, L.J., O'Connor, K., Larson,
R.S., and Springer, T.A. (1987) EMBO J. 6, 4023-4028
13. Briesewitz, R., Epstein, M.R., and Marcantonio, E.E.,
(1993) J.Biol.Chem. 268, 2989-2996
14. Ziober, B.L., Vu, M.P., Waleh, N., Crawford, J., Lin,
C.S., and Kramer, R.H. (1993) J.Biol.Chem. 268,
26773-26783
15. Hogervorst, F., Kuikman, I., van Kessel, A.G., and
Sonnenberg, A. (1991) Eur.J.Biochem. 199, 425-433
16. Takada, Y. and Hemler, M.E. (1989) J.Cell Biol. 109,
397-407
17. Takada, Y., Murphy, E., Pil, P., Chen, C., Ginsberg,
M.H., and Hemler, M.E. (1991) J.Cell Biol. 115,
257-266
18. Van der Vieren, M., Le Trong, H., Wood, C.L., Moore,
P.F., St.John, T., Staunton, D.E., and Gallatin, W.M.
(1995) Immunity. 3, 683-690
CA 02324381 2000-09-29
WO 99/51639 PCT/SE99/00544
32
19. Schnapp, L.M., Breuss, J.M., Ramos, D.M., Sheppard,
D., and Pytela, R. (1995) J.Cell Sci. 108, 537-544
20. Shaw, S.K., Cepek, K.L., Murphy,. E.A., Russell, G.J.,
Brenner, M.B., and Parker, C.M. (1994) J.Biol.Chem.
269, 6016-6025
21. Suzuki, S., Argraves, W.S., Arai, H., Languino, L.R.,
Pierschbacher, M.D., and Ruoslahti, E. (1987)
J.Biol.Chem. 262, 14080-14085
22. Ignatius, M.J., Large, T.H., Houde, M., Tawil, J.W.,
Barton, A., Esch, F., Carbonetto, S., and Reichardt,
L.F. (1990) J.Cell Biol. 111, 709-720
23. Gullberg, D., Gehlsen, K.R., Turner, D.C., Ahlen, K.,
Zijenah, L.S., Barnes, M.J., and Rubin, K. (1992)
EMBO J. 11, 3865-3873
24. Staaz, W.D., Rajpara, S.M., Wayner, E.A., Carter,
W.G., and Santoro, S.A. (1989) J.CellfBiol. 108,
1917-1924
25. Holmvall, K., Camper, L., Johansson, S., Rubin, K.,
Kimura, J.H., and Lundgren-Akerlund, E. (1995)
Exp.Cell Res. 221, 496-503
26. Forsberg, E., Ek, B., Engstrom, A., and Johansson, S.
(1994) Exp.Cell Res. 213, 183-190
27. Wayner, E.A. and Carter, W.G. (1987) J.Cell Biol.
105, 1873-1884
28. Weitzman, J.B., Pasqualini, R., Takada, Y., and
Hemler, M.E. (1993) J.Biol.Chem. 268, 8651-8657
29. Elices, M.J. and Hemler, M.E. (1989)
Proc.Natl.Acad.Sci.U.S.A. 86, 9906-9910
30. Languino, L.R., Colella, S., Zanetti, A., Andrieux,
A., Ryckewaert, J.J., Charon, M.H., Marchisio, P.C.,
Plow, E.F., Ginsberg, M.H., Marguerie, G., and et al
(1989) Blood 73, 734-742
31. Tuckwell, D.S., Humphries, M.J., and Brass, A. (1994)
Cell Adhes.Commun. 2, 385-402
32. Springer, T.A. (1997) Proc.Natl.Acad.Sci.U.S.A. 94,
65-72
CA 02324381 2000-09-29
WO 99/51639 PCT/SE99/00544
33
33. Colombatti, A., Bonaldo, P., and Doliana, R. (1993)
Matrix 13, 297-306
34. Lee, C.H., Bradley, G., and Ling, V. (1995) Cell
Growth Differ. 6, 347-354
35. Calderwood, D.A., Tuckwell, D.S., and Humphries, M.J.
(1995) Biochem.Soc.Trans. 23, 504S
36. Kern, A., Eble, J., Golbik, R., and Kuhn, K. (1993)
Eur.J.Biochem. 215, 151-159
37. Tuckwell, D.S., Reid, K.B., Barnes, M.J., and
Humphries, M.J. (1996) Eur.J.Biochem. 241, 732-739
38. Kamata, T. and Takada, Y. (1994) J.Biol.Chem. 269,
26006-26010
39. DUrr, J., Goodman, S., Potocnik, A., von der Mark,
H., and von der Mark, K. (1993) Exp.Cell Res. 207,
235-244
40. Salter, D.M., Hughes, D.E., Simpson, A., and Gardner,
D.L. (1992) Br.J.Rheumatol. 31, 231-234
41. Woods, V.L.J., Schreck, P.J., Gesink, D.S., Pacheco,
H.O., Amiel, D., Akeson, W.H., and Lotz, M. (1994)
Arthritis Rheum. 37, 537-544
42. Camper, L., Heinegard, D., and Lundgren-Akerlund, E.
(1997) J.Cell Biol 138, 1159-1167
43. Hemler, M.E., Sanchez Madrid, F., Flotte, T.J.,
Krensky, A.M., Burakoff, S.J., Bhan, A.K., Springer,
T.A., and Strominger, J.L. (1984) J.Immunol. 132,
3011-3018
44. Bottger, B.A., Hedin, U., Johansson, S., and Thyberg,
J. (1989) Differentiation. 41, 158-167
45. Sommarin, Y. and Heineg$rd, D. (1983) Biochem.J. 214,
777-784
46. HAuselmann, H.J., Aydelotte, M.B., Schumacher, B.L.,
Kuettner, K.E., Gitelis, S.H., and Thonar, E.J.M.A.
(1992) Matrix 12, 116-129
47. Miller, E.J. (1972) Biochemistry 11, 4903-4909
48. Wessel, D. and Flugge, U.I. (1984) Anal.Biochem. 138,
141-143
CA 02324381 2000-09-29
WO 99/51639 PCT/SE99/00544
34
49. Blobel, G. and Dobberstein, B. (1975) J.Cell Biol.
67, 835-851
50. Hellman, U. (1997) in Protein structure analysis.
Preparation, characterization, and microsequencing
(Kamp, R.M., Choli-Papadopoulou, T., and Wittmann-
Liebold, B., eds) pp. 97-104, Spriner-Verlag,
Heidelberg
51. Charles, I.G., Palmer, R.M., Hickery, M.S., Bayliss,
M.T., Chubb, A.P., Hall, V.S., Moss, D.W., and
Moncada, S. (1993) Proc.Natl.Acad.Sci.U.S.A. 90,
11419-11423
52. Tuckwell, D.S., Brass, A., and Humphries, M.J. (1992)
Biochem.J. 285, 325-331
53. Dedhar, S. and Hannigan, G.E. (1996) Curr.Opin.Cell
Biol. 8, 657-669
54. Hughes, P.E., O'Toole, T.E., Ylanne, J., Shattil,
S.J., and Ginsberg, M.H. (1995) J.Biol.Chem. 270,
12411-12417
55. Puzon McLaughlin, W., Yednock, T.A., and Takada, Y.
(1996) J.Biol.Chem. 271, 16580-16585
56. O'Toole, T.E., Katagiri, Y., Faull, R.J., Peter, K.,
Tamura, R., Quaranta, V., Loftus, J.C., Shattil,
S.J., and Ginsberg, M.H. (1994) J.Cell Biol. 124,
1047-1059
57. De Melker, A.A., Kramer, D., Kuikman, I., and
Sonnenberg, A. (1997) Biochem J 529-537
58. Rojiani, M.V., Finlay, B.B., Gray, V., and Dedhar, S.
(1991) Biochemistry 30, 9859-9866
59. Coppolino, M.G., Woodside, M.J., Demaurex, N.,
Grinstein, S., St Arnaud, R., and Dedhar, S. (1997)
Nature 386, 843-847
60. Hynes, R.O. (1992) Curr.Opin.Genet.Dev. 2, 621-624
61. Santoro, S.A. (1986) Cell 46, 913-920
62. Languino, L.R., Gehlsen, K.R., Wayner, E., Carter,
W.G., Engvall, E., and Ruoslahti, E. (1989) J.Ce11
Biol. 109, 2455-2462
CA 02324381 2000-09-29
WO 99/51639 PCT/SE99/00544
63. Yokosaki, Y., Monis, H., Chen, J., and Sheppard, D.
(1996) J.Biol.Chem. 271, 24144-24150
CA 02324381 2001-04-02
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT:
(A) NAME: Cartela AB
(B) STREET: Scheelevagen 22
(C) CITY: S-220 07 Lund
(D) STATE: -
(E) COUNTRY: Sweden
(F) POSTAL CODE (ZIP): -
(G) TELEPHONE: -
(H) TELEFAX: -
(I) TELEX: -
(ii) TITLE OF INVENTION: AN INTEGRIN HETERODIMER AND A SUBUNIT THEREOF
(iii) NUMBER OF SEQUENCES: 6
(iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentln Release #1.0, Version #1.30 (EPO)
(v) CURRENT APPLICATION DATA:
APPLICATION NUMBER: CA 2324381
(vi) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: SE 9801164-6
(B) FILING DATE: 02-APR-1998
(vi) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: SE 9900319-6
(B) FILING DATE: 01-JAN-1999
(2) INFORMATION FOR SEQ ID NO: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3884 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
CAGGTCAGAA ACCGATCAGG CATGGAACTC CCCTTCGTCA CTCACCTGTT CTTGCCCCTG 60
GTGTTCCTGA CAGGTCTCTG CTCCCCCTTT AACCTGGATG AACATCACCC ACGCCTATTC 120
CCAGGGCCAC CAGAAGCTGA ATTTGGATAC AGTGTCTTAC AACATGTTGG GGGTGGACAG 180
CGATGGATGC TGGTGGGCGC CCCCTGGGAT GGGCCTTCAG GCGACCGGAG GGGGGACGTT 240
TATCGCTGCC CTGTAGGGGG GGCCCACAAT GCCCCATGTG CCAAGGGCCA CTTAGGTGAC 300
Page 1 / 14
CA 02324381 2001-04-02
TACCAACTGG GAAATTCATC TCATCCTGCT GTGAATATGC ACCTGGGGAT GTCTCTGTTA 360
GAGACAGATG GTGATGGGGG ATTCATGGCC TGTGCCCCTC TCTGGTCTCG TGCTTGTGGC 420
AGCTCTGTCT TCAGTTCTGG GATATGTGCC CGTGTGGATG CTTCATTCCA GCCTCAGGGA 480
AGCCTGGCAC CCACTGCCCA ACGCTGCCCA ACATACATGG ATGTTGTCAT TGTCTTGGAT 540
GGCTCCAACA GCATCTACCC CTGGTCTGAA GTTCAGACCT TCCTACGAAG ACTGGTAGGG 600
AAACTGTTTA TTGACCCAGA ACAGATACAG GTGGGACTGG TACAGTATGG GGAGAGCCCT 660
GTACATGAGT GGTCCCTGGG AGATTTCCGA ACGAAGGAAG AAGTGGTGAG AGCAGCAAAG 720
AACCTCAGTC GGCGGGAGGG ACGAGAAACA AAGACTGCCC AAGCAATAAT GGTGGCCTGC 780
ACAGAAGGGT TCAGTCAGTC CCATGGGGGC CGACCCGAGG CTGCCAGGCT ACTGGTGGTT 840
GTCACTGATG GAGAGTCCCA TGATGGAGAG GAGCTTCCTG CAGCACTAAA GGCCTGTGAG 900
GCTGGAAGAG TGACACGCTA TGGGATTGCA GTCCTTGGTC ACTACCTCCG GCGGCAGCGA 960
GATCCCAGCT CTTTCCTGAG AGAAATTAGA ACTATTGCCA GTGATCCAGA TGAGCGATTC 1020
TTCTTCAATG TCACAGATGA GGCTGCTCTG ACTGACATTG TGGATGCACT AGGAGATCGG 1080
ATTTTTGGCC TTGAAGGGTC CCATGCAGAA AACGAAAGCT CCTTTGGGCT GGAAATGTCT 1140
CAGATTGGTT TCTCCACTCA TCGGCTAAAG GATGGGATTC TTTTTGGGAT GGTGGGGGCC 1200
TATGACTGGG GAGGCTCTGT GCTATGGCTT GAAGGAGGCC ACCGCCTTTT CCCCCCACGA 1260
ATGGCACTGG AAGACGAGTT CCCCCCTGCA CTGCAGAACC ATGCAGCCTA CCTGGGTTAC 1320
TCTGTTTCTT CCATGCTTTT GCGGGGTGGA CGCCGCCTGT TTCTCTCTGG GGCTCCTCGA 1380
TTTAGACATC GAGGAAAAGT CATCGCCTTC CAGCTTAAGA AAGATGGGGC TGTGAGGGTT 1440
GCCCAGAGCC TCCAGGGGGA GCAGATTGGT TCATACTTTG GCAGTGAGCT CTGCCCATTG 1500
GATACAGATA GGGATGGAAC AACTGATGTC TTACTTGTGG CTGCCCCCAT GTTCCTGGGA 1560
CCCCAGAACA AGGAAACAGG ACGTGTTTAT GTGTATCTGG TAGGCCAGCA GTCCTTGCTG 1620
ACCCTCCAAG GAACACTTCA GCCAGAACCC CCCCAGGATG CTCGGTTTGG CTTTGCCATG 1680
GGAGCTCTTC CTGATCTGAA CCAAGATGGT TTTGCTGATG TGGCTGTGGG GGCGCCTCTG 1740
GAAGATGGGC ACCAGGGAGC ACTGTACCTG TACCATGGAA CCCAGAGTGG AGTCAGGCCC 1800
CATCCTGCCC AGAGGATTGC TGCTGCCTCC ATGCCACATG CCCTCAGCTA CTTTGGCCGA 1860
AGTGTGGATG GTCGGCTAGA TCTGGATGGA GATGATCTGG TCGATGTGGC TGTGGGTGCC 1920
CAGGGGGCAG CCATCCTGCT CAGCTCCCGG CCCATTGTCC ATCTGACCCC ATCACTGGAG 1980
GTGACCCCAC AGGCCATCAG TGTGGTTCAG AGGGACTGTA GGCGGCGAGG CCAAGAAGCA 2040
GTCTGTCTGA CTGCAGCCCT TTGCTTCCAA GTGACCTCCC GTACTCCTGG TCGCTGGGAT 2100
CACCAATTCT ACATGAGGTT CACCGCATCA CTGGATGAAT GGACTGCTGG GGCACGTGCA 2160
Page 2 / 14
CA 02324381 2001-04-02
GCATTTGATG GCTCTGGCCA GAGGTTGTCC CCTCGGAGGC TCCGGCTCAG TGTGGGGAAT 2220
GTCACTTGTG AGCAGCTACA CTTCCATGTG CTGGATACAT CAGATTACCT CCGGCCAGTG 2280
GCCTTGACTG TGACCTTTGC CTTGGACAAT ACTACAAAGC CAGGGCCTGT GCTGAATGAG 2340
GGCTCACCCA CCTCTATACA AAAGCTGGTC CCCTTCTCAA AGGATTGTGG CCCTGACAAT 2400
GAATGTGTCA CAGACCTGGT GCTTCAAGTG AATATGGACA TCAGAGGCTC CAGGAAGGCC 2460
CCATTTGTGG TTCGAGGTGG CCGGCGGAAA GTGCTGGTAT CTACAACTCT GGAGAACAGA 2520
AAGGAAAATG CTTACAATAC GAGCCTGAGT ATCATCTTCT CTAGAAACCT CCACCTGGCC 2580
AGTCTCACTC CTCAGAGAGA GAGCCCAATA AAGGTGGAAT GTGCCGCCCC TTCTGCTCAT 2640
GCCCGGCTCT GCAGTGTGGG GCATCCTGTC TTCCAGACTG GAGCCAAGGT GACCTTTCTG 2700
CTAGAGTTTG AGTTTAGCTG CTCCTCTCTC CTGAGCCAGG TCTTTGGGAA GCTGACTGCC 2760
AGCAGTGACA GCCTGGAGAG AAATGGCACC CTTCAAGAAA ACACAGCCCA GACCTCAGCC 2820
TACATCCAAT ATGAGCCCCA CCTCCTGTTC TCTAGTGAGT CTACCCTGCA CCGCTATGAG 2880
GTTCACCCAT ATGGGACCCT CCCAGTGGGT CCTGGCCCAG AATTCAAAAC CACTCTCAGG 2940
GTTCAGAACC TAGGCTGCTA TGTGGTCAGT GGCCTCATCA TCTCAGCCCT CCTTCCAGCT 3000
GTGGCCCATG GGGGCAATTA CTTCCTATCA CTGTCTCAAG TCATCACTAA CAATGCAAGC 3060
TGCATAGTGC AGAACCTGAC TGAACCCCCA GGCCCACCTG TGCATCCAGA GGAGCTTCAA 3120
CACACAAACA GACTGAATGG GAGCAATACT CAGTGTCAGG TGGTGAGGTG CCACCTTGGG 3180
CAGCTGGCAA AGGGGACTGA GGTCTCTGTT GGACTATTGA GGCTGGTTCA CAATGAATTT 3240
TTCCGAAGAG CCAAGTTCAA GTCCCTGACG GTGGTCAGCA CCTTTGAGCT GGGAACCGAA 3300
GAGGGCAGTG TCCTACAGCT GACTGAAGCC TCCCGTTGGA GTGAGAGCCT CTTGGAGGTG 3360
GTTCAGACCC GGCCTATCCT CATCTCCCTG TGGATCCTCA TAGGCAGTGT CCTGGGAGGG 3420
TTGCTCCTGC TTGCTCTCCT TGTCTTCTGC CTGTGGAAGC TTGGCTTCTT TGCCCATAAG 3480
AAAATCCCTG AGGAAGAAAA AAGAGAAGAG AAGTTGGAGC AATGAATGTA GAATAAGGGT 3540
CTAGAAAGTC CTCCCTGGCA GCTTTCTTCA AGAGACTTGC ATAAAAGCAG AGGTTTGGGG 3600
GCTCAGATGG GACAAGAAGC CGCCTCTGGA CTATCTCCCC AGACCAGCAG CCTGACTTGA 3660
CTTTTGAGTC CTAGGGATGC TGCTGGCTAG AGATGAGGCT TTACCTCAGA CAAGAAGAGC 3720
TGGCACCAAA ACTAGCCATG CTCCCACCCT CTGCTTCCCT CCTCCTCGTG ATCCTGGTTC 3780
CATAGCCAAC ACTGGGGCTT TTGTTTGGGG TCCTTTTATC CCCAGGAATC AATAATTTTT 3840
TTGCCTAGGA AAAAAAAAAG CGGCCGCGAA TTCGATATCA AGCT 3884
(2) INFORMATION FOR SEQ ID NO: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3779 base pairs
Page 3 / 14
CA 02324381 2001-04-02
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
CAGGTCAGAA ACCGATCAGG CATGGAACTC CCCTTCGTCA CTCACCTGTT CTTGCCCCTG 60
GTGTTCCTGA CAGGTCTCTG CTCCCCCTTT AACCTGGATG AACATCACCC ACGCCTATTC 120
CCAGGGCCAC CAGAAGCTGA ATTTGGATAC AGTGTCTTAC AACATGTTGG GGGTGGACAG 180
CGATGGATGC TGGTGGGCGC CCCCTGGGAT GGGCCTTCAG GCGACCGGAG GGGGGACGTT 240
TATCGCTGCC CTGTAGGGGG GGCCCACAAT GCCCCATGTG CCAAGGGCCA CTTAGGTGAC 300
TACCAACTGG GAAATTCATC TCATCCTGCT GTGAATATGC ACCTGGGGAT GTCTCTGTTA 360
GAGACAGATG GTGATGGGGG ATTCATGGCC TGTGCCCCTC TCTGGTCTCG TGCTTGTGGC 420
AGCTCTGTCT TCAGTTCTGG GATATGTGCC CGTGTGGATG CTTCATTCCA GCCTCAGGGA 480
AGCCTGGCAC CCACTGCCCA ACGCTGCCCA ACATACATGG ATGTTGTCAT TGTCTTGGAT 540
GGCTCCAACA GCATCTACCC CTGGTCTGAA GTTCAGACCT TCCTACGAAG ACTGGTAGGG 600
AAACTGTTTA TTGACCCAGA ACAGATACAG GTGGGACTGG TACAGTATGG GGAGAGCCCT 660
GTACATGAGT GGTCCCTGGG AGATTTCCGA ACGAAGGAAG AAGTGGTGAG AGCAGCAAAG 720
AACCTCAGTC GGCGGGAGGG ACGAGAAACA AAGACTGCCC AAGCAATAAT GGTGGCCTGC 780
ACAGAAGGGT TCAGTCAGTC CCATGGGGGC CGACCCGAGG CTGCCAGGCT ACTGGTGGTT 840
GTCACTGATG GAGAGTCCCA TGATGGAGAG GAGCTTCCTG CAGCACTAAA GGCCTGTGAG 900
GCTGGAAGAG TGACACGCTA TGGGATTGCA GTCCTTGGTC ACTACCTCCG GCGGCAGCGA 960
GATCCCAGCT CTTTCCTGAG AGAAATTAGA ACTATTGCCA GTGATCCAGA TGAGCGATTC 1020
TTCTTCAATG TCACAGATGA GGCTGCTCTG ACTGACATTG TGGATGCACT AGGAGATCGG 1080
ATTTTTGGCC TTGAAGGGTC CCATGCAGAA AACGAAAGCT CCTTTGGGCT GGAAATGTCT 1140
CAGATTGGTT TCTCCACTCA TCGGCTAAAG GATGGGATTC TTTTTGGGAT GGTGGGGGCC 1200
TATGACTGGG GAGGCTCTGT GCTATGGCTT GAAGGAGGCC ACCGCCTTTT CCCCCCACGA 1260
ATGGCACTGG AAGACGAGTT CCCCCCTGCA CTGCAGAACC ATGCAGCCTA CCTGGGTTAC 1320
TCTGTTTCTT CCATGCTTTT GCGGGGTGGA CGCCGCCTGT TTCTCTCTGG GGCTCCTCGA 1380
TTTAGACATC GAGGAAAAGT CATCGCCTTC CAGCTTAAGA AAGATGGGGC TGTGAGGGTT 1440
GCCCAGAGCC TCCAGGGGGA GCAGATTGGT TCATACTTTG GCAGTGAGCT CTGCCCATTG 1500
GATACAGATA GGGATGGAAC AACTGATGTC TTACTTGTGG CTGCCCCCAT GTTCCTGGGA 1560
Page 4 / 14
CA 02324381 2001-04-02
CCCCAGAACA AGGAAACAGG ACGTGTTTAT GTGTATCTGG TAGGCCAGCA GTCCTTGCTG 1620
ACCCTCCAAG GAACACTTCA GCCAGAACCC CCCCAGGATG CTCGGTTTGG CTTTGCCATG 1680
GGAGCTCTTC CTGATCTGAA CCAAGATGGT TTTGCTGATG TGGCTGTGGG GGCGCCTCTG 1740
GAAGATGGGC ACCAGGGAGC ACTGTACCTG TACCATGGAA CCCAGAGTGG AGTCAGGCCC 1800
CATCCTGCCC AGAGGATTGC TGCTGCCTCC ATGCCACATG CCCTCAGCTA CTTTGGCCGA 1860
AGTGTGGATG GTCGGCTAGA TCTGGATGGA GATGATCTGG TCGATGTGGC TGTGGGTGCC 1920
CAGGGGGCAG CCATCCTGCT CAGCTCCCGG CCCATTGTCC ATCTGACCCC ATCACTGGAG 1980
GTGACCCCAC AGGCCATCAG TGTGGTTCAG AGGGACTGTA GGCGGCGAGG CCAAGAAGCA 2040
GTCTGTCTGA CTGCAGCCCT TTGCTTCCAA GTGACCTCCC GTACTCCTGG TCGCTGGGAT 2100
CACCAATTCT ACATGAGGTT CACCGCATCA CTGGATGAAT GGACTGCTGG GGCACGTGCA 2160
GCATTTGATG GCTCTGGCCA GAGGTTGTCC CCTCGGAGGC TCCGGCTCAG TGTGGGGAAT 2220
GTCACTTGTG AGCAGCTACA CTTCCATGTG CTGGATACAT CAGATTACCT CCGGCCAGTG 2280
GCCTTGACTG TGACCTTTGC CTTGGACAAT ACTACAAAGC CAGGGCCTGT GCTGAATGAG 2340
GGCTCACCCA CCTCTATACA AAAGCTGGTC CCCTTCTCAA AGGATTGTGG CCCTGACAAT 2400
GAATGTGTCA CAGACCTGGT GCTTCAAGTG AATATGGACA TCAGAGGCTC CAGGAAGGCC 2460
CCATTTGTGG TTCGAGGTGG CCGGCGGAAA GTGCTGGTAT CTACAACTCT GGAGAACAGA 2520
AAGGAAAATG CTTACAATAC GAGCCTGAGT ATCATCTTCT CTAGAAACCT CCACCTGGCC 2580
AGTCTCACTC CTCAGAGAGA GAGCCCAATA AAGGTGGAAT GTGCCGCCCC TTCTGCTCAT 2640
GCCCGGCTCT GCAGTGTGGG GCATCCTGTC TTCCAGACTG GAGCCAAGGT GACCTTTCTG 2700
CTAGAGTTTG AGTTTAGCTG CTCCTCTCTC CTGAGCCAGG TCTTTGGGAA GCTGACTGCC 2760
AGCAGTGACA GCCTGGAGAG AAATGGCACC CTTCAAGAAA ACACAGCCCA GACCTCAGCC 2820
TACATCCAAT ATGAGCCCCA CCTCCTGTTC TCTAGTGAGT CTACCCTGCA CCGCTATGAG 2880
GTTCACCCAT ATGGGACCCT CCCAGTGGGT CCTGGCCCAG AATTCAAAAC CACTCTCAGG 2940
ACTAACAATG CAAGCTGCAT AGTGCAGAAC CTGACTGAAC CCCCAGGCCC ACCTGTGCAT 3000
CCAGAGGAGC TTCAACACAC AAACAGACTG AATGGGAGCA ATACTCAGTG TCAGGTGGTG 3060
AGGTGCCACC TTGGGCAGCT GGCAAAGGGG ACTGAGGTCT CTGTTGGACT ATTGAGGCTG 3120
GTTCACAATG AATTTTTCCG AAGAGCCAAG TTCAAGTCCC TGACGGTGGT CAGCACCTTT 3180
GAGCTGGGAA CCGAAGAGGG CAGTGTCCTA CAGCTGACTG AAGCCTCCCG TTGGAGTGAG 3240
AGCCTCTTGG AGGTGGTTCA GACCCGGCCT ATCCTCATCT CCCTGTGGAT CCTCATAGGC 3300
AGTGTCCTGG GAGGGTTGCT CCTGCTTGCT CTCCTTGTCT TCTGCCTGTG GAAGCTTGGC 3360
TTCTTTGCCC ATAAGAAAAT CCCTGAGGAA GAAAAAAGAG AAGAGAAGTT GGAGCAATGA 3420
Page 5 / 14
CA 02324381 2001-04-02
ATGTAGAATA AGGGTCTAGA AAGTCCTCCC TGGCAGCTTT CTTCAAGAGA CTTGCATAAA 3480
AGCAGAGGTT TGGGGGCTCA GATGGGACAA GAAGCCGCCT CTGGACTATC TCCCCAGACC 3540
AGCAGCCTGA CTTGACTTTT GAGTCCTAGG GATGCTGCTG GCTAGAGATG AGGCTTTACC 3600
TCAGACAAGA AGAGCTGGCA CCAAAACTAG CCATGCTCCC ACCCTCTGCT TCCCTCCTCC 3660
TCGTGATCCT GGTTCCATAG CCAACACTGG GGCTTTTGTT TGGGGTCCTT TTATCCCCAG 3720
GAATCAATAA TTTTTTTGCC TAGGAAAAAA AAAAGCGGCC GCGAATTCGA TATCAAGCT 3779
(2) INFORMATION FOR SEQ ID NO: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 143 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
GGGGCATATG GTTCAGAACC TGGGTTGCTA CGTTGTTTCC GGTCTGATCA TCTCCGCTCT 60
GCTGCCGGCT GTTGCTCACG GTGGTAACTA CTTCCTAAGC TTGTCCCAGG TTATCAGCGG 120
CCTGGTGCCG CGCGGATCCC CCC 143
(2) INFORMATION FOR SEQ ID NO: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1167 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
Met Glu Leu Pro Phe Val Thr His Leu Phe Leu Pro Leu Val Phe Leu
1 5 10 15
Thr Gly Leu Cys Ser Pro Phe Asn Leu Asp Glu His His Pro Arg Leu
20 25 30
Phe Pro Gly Pro Pro Glu Ala Glu Phe Gly Tyr Ser Val Leu Gln His
35 40 45
Val Gly Gly Gly Gln Arg Trp Met Leu Val Gly Ala Pro Trp Asp Gly
50 55 60
Pro Ser Gly Asp Arg Arg Gly Asp Val Tyr Arg Cys Pro Val Gly Gly
65 70 75 80
Page 6 / 14
CA 02324381 2001-04-02
Ala His Asn Ala Pro Cys Ala Lys Gly His Leu Gly Asp Tyr Gln Leu
85 90 95
Gly Asn Ser Ser His Pro Ala Val Asn Met His Leu Gly Met Ser Leu
100 105 110
Leu Glu Thr Asp Gly Asp Gly Gly Phe Met Ala Cys Ala Pro Leu Trp
115 120 125
Ser Arg Ala Cys Gly Ser Ser Val Phe Ser Ser Gly Ile Cys Ala Arg
130 135 140
Val Asp Ala Ser Phe Gln Pro Gln Gly Ser Leu Ala Pro Thr Ala Gln
145 150 155 160
Arg Cys Pro Thr Tyr Met Asp Val Val Ile Val Leu Asp Gly Ser Asn
165 170 175
Ser Ile Tyr Pro Trp Ser Glu Val Gln Thr Phe Leu Arg Arg Leu Val
180 185 190
Gly Lys Leu Phe Ile Asp Pro Glu Gln Ile Gln Val Gly Leu Val Gln
195 200 205
Tyr Gly Glu Ser Pro Val His Glu Trp Ser Leu Gly Asp Phe Arg Thr
210 215 220
Lys Glu Glu Val Val Arg Ala Ala Lys Asn Leu Ser Arg Arg Glu Gly
225 230 235 240
Arg Glu Thr Lys Thr Ala Gln Ala Ile Met Val Ala Cys Thr Glu Gly
245 250 255
Phe Ser Gln Ser His Gly Gly Arg Pro Glu Ala Ala Arg Leu Leu Val
260 265 270
Val Val Thr Asp Gly Glu Ser His Asp Gly Glu Glu Leu Pro Ala Ala
275 280 285
Leu Lys Ala Cys Glu Ala Gly Arg Val Thr Arg Tyr Gly Ile Ala Val
290 295 300
Leu Gly His Tyr Leu Arg Arg Gln Arg Asp Pro Ser Ser Phe Leu Arg
305 310 315 320
Glu Ile Arg Thr Ile Ala Ser Asp Pro Asp Glu Arg Phe Phe Phe Asn
325 330 335
Val Thr Asp Glu Ala Ala Leu Thr Asp Ile Val Asp Ala Leu Gly Asp
340 345 350
Arg Ile Phe Gly Leu Glu Gly Ser His Ala Glu Asn Glu Ser Ser Phe
355 360 365
Gly Leu Glu Met Ser Gln Ile Gly Phe Ser Thr His Arg Leu Lys Asp
370 375 380
Gly Ile Leu Phe Gly Met Val Gly Ala Tyr Asp Trp Gly Gly Ser Val
385 390 395 400
Leu Trp Leu Glu Gly Gly His Arg Leu Phe Pro Pro Arg Met Ala Leu
405 410 415
Page 7/ 14
CA 02324381 2001-04-02
Glu Asp Glu Phe Pro Pro Ala Leu Gln Asn His Ala Ala Tyr Leu Gly
420 425 430
Tyr Ser Val Ser Ser Met Leu Leu Arg Gly Gly Arg Arg Leu Phe Leu
435 440 445
Ser Gly Ala Pro Arg Phe Arg His Arg Gly Lys Val Ile Ala Phe Gln
450 455 460
Leu Lys Lys Asp Gly Ala Val Arg Val Ala Gln Ser Leu Gln Gly Glu
465 470 475 480
Gln Ile Gly Ser Tyr Phe Gly Ser Glu Leu Cys Pro Leu Asp Thr Asp
485 490 495
Arg Asp Gly Thr Thr Asp Val Leu Leu Val Ala Ala Pro Met Phe Leu
500 505 510
Gly Pro Gln Asn Lys Glu Thr Gly Arg Val Tyr Val Tyr Leu Val Gly
515 520 525
Gln Gln Ser Leu Leu Thr Leu Gln Gly Thr Leu Gln Pro Glu Pro Pro
530 535 540
Gln Asp Ala Arg Phe Gly Phe Ala Met Gly Ala Leu Pro Asp Leu Asn
545 550 555 560
Gln Asp Gly Phe Ala Asp Val Ala Val Gly Ala Pro Leu Glu Asp Gly
565 570 575
His Gln Gly Ala Leu Tyr Leu Tyr His Gly Thr Gln Ser Gly Val Arg
580 585 590
Pro His Pro Ala Gln Arg Ile Ala Ala Ala Ser Met Pro His Ala Leu
595 600 605
Ser Tyr Phe Gly Arg Ser Val Asp Gly Arg Leu Asp Leu Asp Gly Asp
610 615 620
Asp Leu Val Asp Val Ala Val Gly Ala Gln Gly Ala Ala Ile Leu Leu
625 630 635 640
Ser Ser Arg Pro Ile Val His Leu Thr Pro Ser Leu Glu Val Thr Pro
645 650 655
Gln Ala Ile Ser Val Val Gln Arg Asp Cys Arg Arg Arg Gly Gln Glu
660 665 670
Ala Val Cys Leu Thr Ala Ala Leu Cys Phe Gln Val Thr Ser Arg Thr
675 680 685
Pro Gly Arg Trp Asp His Gln Phe Tyr Met Arg Phe Thr Ala Ser Leu
690 695 700
Asp Glu Trp Thr Ala Gly Ala Arg Ala Ala Phe Asp Gly Ser Gly Gln
705 710 715 720
Arg Leu Ser Pro Arg Arg Leu Arg Leu Ser Val Gly Asn Val Thr Cys
725 730 735
Glu Gln Leu His Phe His Val Leu Asp Thr Ser Asp Tyr Leu Arg Pro
740 745 750
Page 8 / 14
CA 02324381 2001-04-02
Val Ala Leu Thr Val Thr Phe Ala Leu Asp Asn Thr Thr Lys Pro Gly
755 760 765
Pro Val Leu Asn Glu Gly Ser Pro Thr Ser Ile Gln Lys Leu Val Pro
770 775 780
Phe Ser Lys Asp Cys Gly Pro Asp Asn Glu Cys Val Thr Asp Leu Val
785 790 795 800
Leu Gln Val Asn Met Asp Ile Arg Gly Ser Arg Lys Ala Pro Phe Val
805 810 815
Val Arg Gly Gly Arg Arg Lys Val Leu Val Ser Thr Thr Leu Giu Asn
820 825 830
Arg Lys Glu Asn Ala Tyr Asn Thr Ser Leu Ser Ile Ile Phe Ser Arg
835 840 845
Asn Leu His Leu Ala Ser Leu Thr Pro Gln Arg Glu Ser Pro Ile Lys
850 855 860
Val Glu Cys Ala Ala Pro Ser Ala His Ala Arg Leu Cys Ser Val Gly
865 870 875 880
His Pro Val Phe Gln Thr Gly Ala Lys Val Thr Phe Leu Leu Glu Phe
885 890 895
Glu Phe Ser Cys Ser Ser Leu Leu Ser Gln Val Phe Gly Lys Leu Thr
900 905 910
Ala Ser Ser Asp Ser Leu Glu Arg Asn Gly Thr Leu Gln Glu Asn Thr
915 920 925
Ala Gln Thr Ser Ala Tyr Ile Gln Tyr Glu Pro His Leu Leu Phe Ser
930 935 940
Ser Glu Ser Thr Leu His Arg Tyr Glu Val His Pro Tyr Gly Thr Leu
945 950 955 960
Pro Val Gly Pro Gly Pro Glu Phe Lys Thr Thr Leu Arg Val Gln Asn
965 970 975
Leu Gly Cys Tyr Val Val Ser Gly Leu Ile Ile Ser Ala Leu Leu Pro
980 985 990
Ala Val Ala His Gly Gly Asn Tyr Phe Leu Ser Leu Ser Gln Val Ile
995 1000 1005
Thr Asn Asn Ala Ser Cys Ile Val Gln Asn Leu Thr Glu Pro Pro Gly
1010 1015 1020
Pro Pro Val His Pro Glu Glu Leu Gln His Thr Asn Arg Leu Asn Gly
1025 1030 1035 1040
Ser Asn Thr Gln Cys Gln Val Val Arg Cys His Leu Gly Gln Leu Ala
1045 1050 1055
Lys Gly Thr Glu Val Ser Val Gly Leu Leu Arg Leu Val His Asn Glu
1060 1065 1070
Phe Phe Arg Arg Ala Lys Phe Lys Ser Leu Thr Val Val Ser Thr Phe
1075 1080 1085
Page 9 / 14
CA 02324381 2001-04-02
Glu Leu Gly Thr Glu Glu Gly Ser Val Leu Gln Leu Thr Glu Ala Ser
1090 1095 1100
Arg Trp Ser Glu Ser Leu Leu Giu Val Val Gln Thr Arg Pro Ile Leu
1105 1110 1115 1120
Ile Ser Leu Trp Ile Leu Ile Gly Ser Val Leu Gly Gly Leu Leu Leu
1125 1130 1135
Leu Ala Leu Leu Val Phe Cys Leu Trp Lys Leu Gly Phe Phe Ala His
1140 1145 1150
Lys Lys Ile Pro Glu Glu Glu Lys Arg Glu Glu Lys Leu Glu Gln
1155 1160 1165
(2) INFORMATION FOR SEQ ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1132 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
Met Glu Leu Pro Phe Val Thr His Leu Phe Leu Pro Leu Val Phe Leu
1 5 10 15
Thr Gly Leu Cys Ser Pro Phe Asn Leu Asp Glu His His Pro Arg Leu
20 25 30
Phe Pro Gly Pro Pro Glu Ala Glu Phe Gly Tyr Ser Val Leu Gln His
35 40 45
Val Gly Gly Gly Gln Arg Trp Met Leu Val Gly Ala Pro Trp Asp Gly
50 55 60
Pro Ser Gly Asp Arg Arg Gly Asp Val Tyr Arg Cys Pro Val Gly Gly
65 70 75 80
Ala His Asn Ala Pro Cys Ala Lys Gly His Leu Gly Asp Tyr Gln Leu
85 90 95
Gly Asn Ser Ser His Pro Ala Val Asn Met His Leu Gly Met Ser Leu
100 105 110
Leu Glu Thr Asp Gly Asp Gly Gly Phe Met Ala Cys Ala Pro Leu Trp
115 120 125
Ser Arg Ala Cys Gly Ser Ser Val Phe Ser Ser Gly Ile Cys Ala Arg
130 135 140
Val Asp Ala Ser Phe Gln Pro Gln Gly Ser Leu Ala Pro Thr Ala Gln
145 150 155 160
Arg Cys Pro Thr Tyr Met Asp Val Val Ile Val Leu Asp Gly Ser Asn
165 170 175
Page 10 / 14
CA 02324381 2001-04-02
Ser Ile Tyr Pro Trp Ser Glu Val Gln Thr Phe Leu Arg Arg Leu Val
180 185 190
Gly Lys Leu Phe Ile Asp Pro Glu Gln Ile Gln Val Gly Leu Val Gln
195 200 205
Tyr Gly Glu Ser Pro Val His Glu Trp Ser Leu Gly Asp Phe Arg Thr
210 215 220
Lys Glu Glu Val Val Arg Ala Ala Lys Asn Leu Ser Arg Arg Glu Gly
225 230 235 240
Arg Glu Thr Lys Thr Ala Gln Ala Ile Met Val Ala Cys Thr Glu Gly
245 250 255
Phe Ser Gln Ser His Gly Gly Arg Pro Glu Ala Ala Arg Leu Leu Val
260 265 270
Val Val Thr Asp Gly Glu Ser His Asp Gly Glu Glu Leu Pro Ala Ala
275 280 285
Leu Lys Ala Cys Glu Ala Gly Arg Val Thr Arg Tyr Gly Ile Ala Val
290 295 300
Leu Gly His Tyr Leu Arg Arg Gln Arg Asp Pro Ser Ser Phe Leu Arg
305 310 315 320
Glu Ile Arg Thr Ile Ala Ser Asp Pro Asp Glu Arg Phe Phe Phe Asn
325 330 335
Val Thr Asp Glu Ala Ala Leu Thr Asp Ile Val Asp Ala Leu Gly Asp
340 345 350
Arg Ile Phe Gly Leu Glu Gly Ser His Ala Glu Asn Glu Ser Ser Phe
355 360 365
Gly Leu Glu Met Ser Gln Ile Gly Phe Ser Thr His Arg Leu Lys Asp
370 375 380
Gly Ile Leu Phe Gly Met Val Gly Ala Tyr Asp Trp Gly Gly Ser Val
385 390 395 400
Leu Trp Leu Glu Gly Gly His Arg Leu Phe Pro Pro Arg Met Ala Leu
405 410 415
Glu Asp Glu Phe Pro Pro Ala Leu Gln Asn His Ala Ala Tyr Leu Gly
420 425 430
Tyr Ser Val Ser Ser Met Leu Leu Arg Gly Gly Arg Arg Leu Phe Leu
435 440 445
Ser Gly Ala Pro Arg Phe Arg His Arg Gly Lys Val Ile Ala Phe Gln
450 455 460
Leu Lys Lys Asp Gly Ala Val Arg Val Ala Gln Ser Leu Gln Gly Glu
465 470 475 480
Gln Ile Gly Ser Tyr Phe Gly Ser Glu Leu Cys Pro Leu Asp Thr Asp
485 490 495
Arg Asp Gly Thr Thr Asp Val Leu Leu Val Ala Ala Pro Met Phe Leu
500 505 510
Page 11/ 14
CA 02324381 2001-04-02
Gly Pro Gln Asn Lys Glu Thr Gly Arg Val Tyr Val Tyr Leu Val Giy
515 520 525
Gln Gln Ser Leu Leu Thr Leu Gln Gly Thr Leu Gln Pro Glu Pro Pro
530 535 540
Gln Asp Ala Arg Phe Gly Phe Ala Met Gly Ala Leu Pro Asp Leu Asn
545 550 555 560
Gln Asp Gly Phe Ala Asp Val Ala Val Gly Ala Pro Leu Glu Asp Gly
565 570 575
His Gln Gly Ala Leu Tyr Leu Tyr His Gly Thr Gln Ser Gly Val Arg
580 585 590
Pro His Pro Ala Gln Arg Ile Ala Ala Ala Ser Met Pro His Ala Leu
595 600 605
Ser Tyr Phe Gly Arg Ser Val Asp Gly Arg Leu Asp Leu Asp Gly Asp
610 615 620
Asp Leu Val Asp Val Ala Val Gly Ala Gln Gly Ala Ala Ile Leu Leu
625 630 635 640
Ser Ser Arg Pro Ile Val His Leu Thr Pro Ser Leu Glu Val Thr Pro
645 650 655
Gln Ala Ile Ser Val Val Gln Arg Asp Cys Arg Arg Arg Gly Gln Glu
660 665 670
Ala Val Cys Leu Thr Ala Ala Leu Cys Phe Gln Val Thr Ser Arg Thr
675 680 685
Pro Gly Arg Trp Asp His Gln Phe Tyr Met Arg Phe Thr Ala Ser Leu
690 695 700
Asp Glu Trp Thr Ala Gly Ala Arg Ala Ala Phe Asp Gly Ser Gly Gln
705 710 715 720
Arg Leu Ser Pro Arg Arg Leu Arg Leu Ser Val Gly Asn Val Thr Cys
725 730 735
Glu Gln Leu His Phe His Val Leu Asp Thr Ser Asp Tyr Leu Arg Pro
740 745 750
Val Ala Leu Thr Val Thr Phe Ala Leu Asp Asn Thr Thr Lys Pro Gly
755 760 765
Pro Val Leu Asn Glu Gly Ser Pro Thr Ser Ile Gln Lys Leu Val Pro
770 775 780
Phe Ser Lys Asp Cys Gly Pro Asp Asn Glu Cys Val Thr Asp Leu Val
785 790 795 800
Leu Gln Val Asn Met Asp Ile Arg Gly Ser Arg Lys Ala Pro Phe Val
805 810 815
Val Arg Gly Gly Arg Arg Lys Val Leu Val Ser Thr Thr Leu Glu Asn
820 825 830
Arg Lys Glu Asn Ala Tyr Asn Thr Ser Leu Ser Ile Ile Phe Ser Arg
835 840 845
Page 12 / 14
CA 02324381 2001-04-02
Asn Leu His Leu Ala Ser Leu Thr Pro Gln Arg Glu Ser Pro Ile Lys
850 855 860
Val Glu Cys Ala Ala Pro Ser Ala His Ala Arg Leu Cys Ser Val Gly
865 870 875 880
His Pro Val Phe Gln Thr Gly Ala Lys Val Thr Phe Leu Leu Glu Phe
885 890 895
Glu Phe Ser Cys Ser Ser Leu Leu Ser Gln Val Phe Gly Lys Leu Thr
900 905 910
Ala Ser Ser Asp Ser Leu Glu Arg Asn Gly Thr Leu Gln Glu Asn Thr
915 920 925
Ala Gln Thr Ser Ala Tyr Ile Gln Tyr Glu Pro His Leu Leu Phe Ser
930 935 940
Ser Glu Ser Thr Leu His Arg Tyr Glu Val His Pro Tyr Gly Thr Leu
945 950 955 960
Pro Val Gly Pro Gly Pro Glu Phe Lys Thr Thr Leu Arg Thr Asn Asn
965 970 975
Ala Ser Cys Ile Val Gln Asn Leu Thr Glu Pro Pro Gly Pro Pro Val
980 985 990
His Pro Glu Glu Leu Gln His Thr Asn Arg Leu Asn Gly Ser Asn Thr
995 1000 1005
Gln Cys Gln Val Val Arg Cys His Leu Gly Gln Leu Ala Lys Gly Thr
1010 1015 1020
Glu Val Ser Val Gly Leu Leu Arg Leu Val His Asn Glu Phe Phe Arg
1025 1030 1035 1040
Arg Ala Lys Phe Lys Ser Leu Thr Val Val Ser Thr Phe Glu Leu Gly
1045 1050 1055
Thr Glu Glu Gly Ser Val Leu Gln Leu Thr Glu Ala Ser Arg Trp Ser
1060 1065 1070
Glu Ser Leu Leu Glu Val Val Gln Thr Arg Pro Ile Leu Ile Ser Leu
1075 1080 1085
Trp Ile Leu Ile Gly Ser Val Leu Gly Gly Leu Leu Leu Leu Ala Leu
1090 1095 1100
Leu Val Phe Cys Leu Trp Lys Leu Gly Phe Phe Ala His Lys Lys Ile
1105 1110 1115 1120
Pro Glu Glu Glu Lys Arg Glu Glu Lys Leu Glu Gln
1125 1130
(2) INFORMATION FOR SEQ ID NO: 6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 47 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
Page 13 / 14
CA 02324381 2001-04-02
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:
Gly His Met Val Gln Asn Leu Gly Cys Tyr Val Val Ser Gly Leu Ile
1 5 10 15
Ile Ser Ala Leu Leu Pro Ala Val Ala His Gly Gly Asn Tyr Phe Leu
20 25 30
Ser Leu Ser Gln Val Ile Ser Gly Leu Val Pro Arg Gly Ser Pro
35 40 45
Page 14 / 14
